Drug Profile
Apomigren
Latest Information Update: 12 Dec 2007
Price :
$50
*
At a glance
- Originator Beth Israel Deaconess Medical Center; Harvard Medical School
- Developer ILEX Oncology Inc
- Class Antineoplastics
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 20 Oct 2000 Preclinical development for Solid tumours in USA (Unknown route)